Tempus xH whole genome sequencing for Life Sciences

Read the press release for the launch of our xH assay →

Overview

Tempus xH is an analytically validated1 next-generation sequencing (NGS) test that uses a WGS approach for the detection of actionable oncologic targets in peripheral blood and/or bone marrow samples from target populations with hematopoietic malignancies.
The performance of the Tempus xH assay was established in an analytical validation study using 235 unique specimens, including whole blood, bone marrow, and cell lines. The results were compared against established orthogonal methods to determine the assay’s accuracy and precision.2

Depth of sequencing

Targeting 80X mean autosomal coverage.

Platforms used

 

Illumina NovaSeq X Plus

Accepted sample types

 

Blood or bone marrow (BM)

 

Alterations identified

 

SNVs, Indels, copy number alterations (CNAs ≥5 Mb), and structural variants (SVs)

 

Sensitivity

 

Demonstrated high positive percent agreement (PPA) when compared to orthogonal methods: 97.29% for SNVs/Indels, 92.86% for SVs, and 93.43% for CNAs.2

 

Our science

xH was developed for use in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN), and overlap syndromes (MDS/MPN). It is optimized for myeloid neoplasms and supports disease understanding, biomarker discovery, and therapeutic research.

 

By scaling WGS-based testing for myeloid malignancies, Tempus supports life science researchers to drive innovation, accelerate therapeutic discovery, and shape the future of precision medicine.

High accuracy compared to orthogonal methods

 

The analytical validation of Tempus xH demonstrated high accuracy across all major alteration types when compared to established orthogonal methods. The assay achieved 97.29% PPA for SNVs and Indels against the Tempus xT assay, 92.86% PPA for SVs against the Tempus xR assay and Sanger sequencing, and 93.43% PPA for CNAs against an Oligo-SNP chromosomal microarray.2

Bar chart displays fusions count by category with one major contributor.Bar chart displays fusions count by category with one major contributor.

Reliable and precise results

 

In addition to high accuracy, the xH assay demonstrated excellent precision, ensuring reliable and reproducible results. For SNVs and Indels, the assay achieved a positive predictive value (PPV) of 98.97%, and for SVs, it achieved a PPV of 100%. This high level of precision minimizes false positives and provides confidence in the detected genomic alterations.2

Genomic WGS results matrix showing concordance and discordance for SNV/INDEL, SV, and CNV.Genomic WGS results matrix showing concordance and discordance for SNV/INDEL, SV, and CNV.

References

  1. Analytically validated in a CLIA certified laboratory.
  2. Tempus. Internal Data on file.

The information on this page is intended for life sciences companies and focuses on research and development applications.

This is AI-enabled precision medicine

This is the future of healthcare.